Susan G. Komen® Applauds Bill Introduction; Urges Quick Passage
Susan G. Komen®, the world’s leading breast cancer organization, commends Representative Patty Acomb (D-Minnetonka) and Senator Alice Mann (D-Edina) for introducing legislation that would eliminate financial barriers to clinically appropriate genetic testing, as well as the recommended screenings based on the results of that testing.
Germline testing is a type of test that looks for inherited mutations that have been present in every cell of the body since birth. In the U.S., 5-10% of breast cancers are related to a known inherited gene mutation. The lifetime risk of breast cancer increases 20-49% for women with moderate risk inherited gene mutations and 50% or more for women with high-risk inherited gene mutations.
HF703/SF1302, introduced by Rep. Acomb and Sen. Mann, eliminates the patient out-of-pocket costs for multi-gene panel testing for inherited gene mutations and evidence-based screenings, ensuring individuals have access to critical information regarding their lifetime cancer risk and recommended early detection and cancer surveillance.
“This legislation ensures patients have a better understanding of their lifetime cancer risk and access to needed risk reduction and treatment strategies,” said Molly Guthrie, Vice President of Policy and Advocacy at Susan G. Komen. “Understanding cancer risk shouldn’t depend on financial means. This legislation helps eliminates barriers, empowering individuals with essential knowledge to make informed decisions about their health.”
“This legislation will ensure patients have access to important information concerning their lifetime risk of cancer, allowing them to make key decisions regarding risk reducing strategies and recommended screenings for early detection,” said Rep. Acomb.
Identification of inherited cancer risk can help guide decisions regarding recommended screenings for the early detection of cancer, personalized cancer treatments and risk-reducing medical treatments. Studies have shown an estimated 83% of eligible patients that underwent multigene panel testing had changes to their medical management, including modifications in follow-up and chemotherapy strategy.
“I am happy to champion SF1302, which will ensure Minnesotans are able to access genetic testing and evidence-based screenings without burdensome cost-sharing,” said Sen. Mann. “This legislation will provide vital information to cancer patients, their family members and their medical providers, ultimately improving the outcomes, decreasing cost and time to treat patients diagnosed with cancer.”
